Dyspnea is fairly common among patients receiving ticagrelor, but the side effect is typically mild and transient. More important, ticagrelor therapy appears to have no impact on cardiac or pulmonary function in patients who are free of active lung disease. The findings were published in the July 13, 2010, issue of the Journal of the American College of Cardiology.

In a prespecified subanalysis of the ONSET/OFFSET trial, investigators led by Robert F. Storey, MD, DM, of the University of Sheffield (Sheffield, United Kingdom), looked for any change in cardiopulmonary function in 123 aspirin-treated patients with stable CAD. In a double-blind, double-dummy ....

You must be a member to access this content. To continue reading, please enter your username and password above.

If you have not yet registered, we would like to take this opportunity to welcome you to TCTMD - The Source for Interventional Cardiovascular News & Education.

If you are already a member, please re-enter your username and password above, and then click LOGIN.

For questions regarding the registration process, please refer to our FAQ documentation or contact customer service.